Identification of Potential Biomarkers in Papillary Thyroid Carcinoma Based on Proteomics.

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-11-03 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S465636

Yu Sun, Jiaxuan Sun, Xiaona Gao, Tiefeng Shi, Maoqing Wang

{"title":"Identification of Potential Biomarkers in Papillary Thyroid Carcinoma Based on Proteomics.","authors":"Yu Sun, Jiaxuan Sun, Xiaona Gao, Tiefeng Shi, Maoqing Wang","doi":"10.2147/OTT.S465636","DOIUrl":null,"url":null,"abstract":"Background: To identify biomarkers of papillary thyroid carcinoma (PTC) and explore the possible pathogenic mechanism.Methods: This study included five patients with PTC. Protein expression of cancer tissues and adjacent normal thyroid tissues from each patient were analyzed by TMT proteomics technology. Differentially expressed proteins were identified, and functional annotation of differentially expressed proteins was performed by bioinformatics and pathway enrichment analysis.Results: A total of 639 differentially expressed proteins were identified, including 278 upregulated and 361 downregulated proteins. Six upregulated proteins were identified as potential specific markers of PTC.Conclusion: Differentially expressed proteins may represent new molecular markers of PTC. These differentially expressed proteins and the related pathways may provide new insights into the pathogenic mechanisms of PTC.","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"905-923"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542476/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S465636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To identify biomarkers of papillary thyroid carcinoma (PTC) and explore the possible pathogenic mechanism.

Methods: This study included five patients with PTC. Protein expression of cancer tissues and adjacent normal thyroid tissues from each patient were analyzed by TMT proteomics technology. Differentially expressed proteins were identified, and functional annotation of differentially expressed proteins was performed by bioinformatics and pathway enrichment analysis.

Results: A total of 639 differentially expressed proteins were identified, including 278 upregulated and 361 downregulated proteins. Six upregulated proteins were identified as potential specific markers of PTC.

Conclusion: Differentially expressed proteins may represent new molecular markers of PTC. These differentially expressed proteins and the related pathways may provide new insights into the pathogenic mechanisms of PTC.

查看原文本刊更多论文

基于蛋白质组学鉴定甲状腺乳头状癌的潜在生物标记物

背景：确定甲状腺乳头状癌（PTC）的生物标志物并探索可能的致病机制：确定甲状腺乳头状癌（PTC）的生物标志物，并探讨其可能的致病机制：本研究纳入了五名PTC患者。采用TMT蛋白质组学技术分析了每位患者癌组织和邻近正常甲状腺组织的蛋白质表达。鉴定差异表达的蛋白质，并通过生物信息学和通路富集分析对差异表达的蛋白质进行功能注释：结果：共鉴定出 639 个差异表达蛋白，包括 278 个上调蛋白和 361 个下调蛋白。结果：共鉴定出 639 个差异表达蛋白，包括 278 个上调蛋白和 361 个下调蛋白，其中 6 个上调蛋白被确定为 PTC 的潜在特异性标志物：结论：差异表达蛋白可能是 PTC 的新分子标记物。结论：差异表达的蛋白质可能代表了新的 PTC 分子标记物，这些差异表达的蛋白质及相关通路可能为 PTC 的致病机制提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.